Medifast launches $100M accelerated share repurchase program

MEDIFAST INC

Entered ASR with JPMorgan to repurchase $100M of common stock.
Initial delivery of ~480,000 shares; final settlement expected in Q3 2022.
Repurchase represents ~600,000 shares at May 31 close, about 5% of fully diluted stock.
Funded through available cash and borrowings under existing credit facility.
Approximately 1.4M shares remain available under current repurchase authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.